SIL1 (Gene)

Organism:

Homo sapiens

Synonyms:BAP, ENTREZ:64374, HGNC:24624, MIM:608005, MSS, NM_001037633, NM_022464, NP_001032722, NP_071909, SIL1 nucleotide exchange factor, SIL1, ULG5, XM_011543570, XM_024446164, XP_011541872, XP_024301932

Omim:OMIM:608005

Id:6c37ff92-00b3-5093-a882-afcb89fa8f01

Hgnc:HGNC:24624

Entrez:64374

Ensembl:ENSG00000120725

Description:SIL1 nucleotide exchange factor

This gene encodes a resident endoplasmic reticulum (ER), N-linked glycoprotein with an N-terminal ER targeting sequence, 2 putative N-glycosylation sites, and a C-terminal ER retention signal. This protein functions as a nucleotide exchange factor for another unfolded protein response protein. Mutations in this gene have been associated with Marinesco-Sjogren syndrome. Alternate transcriptional splice variants have been characterized. [provided by RefSeq, Jul 2008]

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View SIL1's neighborhood in the knowledge graph.

Submit

Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with SIL1.

CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using SIL1.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for SIL1.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with SIL1.

Results found

Linked to

	Label	Description
	GSE218773 ABL2 knockdown Hep-G2 2 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE172016 2 V 5 PACLITAXEL HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE102467 3 V 2 PAZOPANIB HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE195568 palbociclib 2 v 10 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE200982 PLAC8 knockout 0 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE48812 sulforaphane 4 v 10 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE255432 7 V 3 IMEGLIMIN MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE142210 11 V 10 PANOBINOSTAT HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE95077 1 V 2 AMILORIDE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE48812 sulforaphane 8 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS

GSE218773 ABL2 knockdown Hep-G2 2 v 0 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE172016 2 V 5 PACLITAXEL HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE102467 3 V 2 PAZOPANIB HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE195568 palbociclib 2 v 10 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE200982 PLAC8 knockout 0 v 2 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE48812 sulforaphane 4 v 10 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE255432 7 V 3 IMEGLIMIN MOUSE UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE142210 11 V 10 PANOBINOSTAT HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE95077 1 V 2 AMILORIDE HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE48812 sulforaphane 8 v 1 human dn

Gene Set (Entity type)

A Gene Set from LINCS

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

Consortium

Community

Resources

CFDE Workbench

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.